Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma.
1. Why is there a need for new combinations of therapies in relapsed/refractory multiple myeloma? (0:09)
2. Could you tell us a little about the study design and what doses were used? (2:51)
3. What were the efficacy and safety findings of the combination? (4:22)
4. What other combined therapies are being considered for future studies? (5:10)
Speaker disclosures: Paul Richardson has nothing to disclose in relation to this video interview.
Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018